Economic costs and quality of life in chronic inflammatory neuropathies in southeast England

European Journal of Neurology

Volumn 21, Issue 1, 2014, Pages 34-39

  Mahdi Rogers, M ^a   Mccrone, P ^a   Hughes, R A C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Cost of illness; Economics; Health related quality of life; Multifocal motor neuropathy; Paraproteinaemic demyelinating neuropathy

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CHRONIC DEMYELINATING POLYRADICULONEUROPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; COST OF ILLNESS; DEMYELINATING NEUROPATHY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; PARAPROTEINAEMIC DEMYELINATING NEUROPATHY; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED KINGDOM;

CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; COST-OF-ILLNESS; ECONOMICS; HEALTH-RELATED QUALITY OF LIFE; MULTIFOCAL MOTOR NEUROPATHY; PARAPROTEINAEMIC DEMYELINATING NEUROPATHY;

AGED; COST OF ILLNESS; ENGLAND; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84890123869     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12245     Document Type: Article

References (31)

1. Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2013; 21: 28-33.
2. Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78: 1349-1353.
3. Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49: 169-174.
4. Lunn MP, Crawford TO, Hughes RA, Griffin JW, Sheikh KA. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002; 125(Pt 4): 904-911.
5. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46: 910-913.
6. Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8: 157-165.
7. Iijima M, Koike H, Hattori N, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79: 1040-1043.
8. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39: 432-438.
9. Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73: 39-45.
10. Cats EA, van der Pol WL, Van den Berg-Vos RM, Wokke JHJ, Franssen H, van den Berg LH. Multifocal motor neuropathy, a population based study in the Netherlands. J Peripher Nerv Syst 2009; 13: 164.
11. Cats EA, Van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75: 818-825.
12. McCrone P, Chisholm D, Knapp M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003; 10: 687-694.
13. Blackhouse G, Gaebel K, Xie F, et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010; 8: 14.
14. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, ed. Measuring Mental Health Needs, 2nd edn. London: Gaskell, 2001: 200-224.
15. EuroQol. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
16. Curtis L. Unit Costs of Health and Social Care. Canterbury, UK: Personal Social Services Research Unit, University of Kent, 2007.
17. Department of Health UK. NHS reference cost 2006-2007. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571.
18. Department of Health UK. National framework agreement for the supply of immunoglobulins (1 June 2007 to 31 May 2008) reference number: M/PHS/05/4342. 2007.
19. BNF. British National Formulary, 54 edn. London: BMJ Group and RPS Publishing, 2007.
20. Weisbrod BA. The evaluation of human capital. J Polit Econ 1961; 69: 425-436.
21. Office of National Statistics. Annual Survey of Hours and Earnings, 2007. http://www.ons.gov.uk/ons/rel/ashe/annual-survey-of-hours-and-earnings/2007-results/stb-ashe-2007.pdf.
22. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK General Population Survey. York: Centre for Health Economics, University of York, 1995.
23. Hughes RA, Gorson KC, Cros D, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74: 651-657.
24. RMC trial. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8: 158-164.
25. Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007; 69: 1680-1687.
26. Kind P, Hardman G, Macran S. UK population norms for EQ-5D, Discussion Paper 172. University of York, 1999.
27. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006; 7(Suppl 2): S96-S104.
28. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112-1118.
29. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006; 77: 973-976.
30. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 2002; 59: 84-91.
31. Dorman PJ, Slattery J, Farrell B, Dennis MS, Sandercock PA. A randomised comparison of the EuroQol and Short Form-36 after stroke. United Kingdom collaborators in the International Stroke Trial. BMJ 1997; 315: 461.